力恩普制药Lean&Leap

NEWS

Supplementary applications for Piperacillin Sodium and Tazobactam Sodium for Injection accepted

2025-04-16 · Company News

← Back to news

In April 2025, supplementary applications (CYHB2550173, CYHB2550174) for Piperacillin Sodium and Tazobactam Sodium for Injection, co-filed with Sinopharm Weiqida, were accepted by CDE, following the acceptance of Amoxicillin Sodium and Clavulanate Potassium for Injection in December 2024.